Advanced

Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer.

Welinder, Charlotte; Jansson, Bo LU ; Lindell, Gert LU and Wenner, Jörgen LU (2015) In Cancer Letters 358(1). p.43-46
Abstract
Cytokeratin 20 (CK20) is a well-established marker for colon epithelium. Herein, we suggest that CK20 is a biomarker for detecting circulating tumor cells (CTCs) in patients with metastatic colorectal cancer. Blood specimens (7.5 mL) were collected during surgery after liver mobilization from 25 patients with colorectal cancer. The FDA approved CellSearch™ system and two panels of antibodies against cytokeratins, cytokeratin 8, 18 and 19 (CK8/18/19) and CK8/18/19/20, were used for the detection of CTCs. All the patients' samples were processed using the anti-CK8/18/19 panel. The number of detected CTCs was low, 52% of the patients lacked CTCs and 40% had ≤ 2 CTCs/7.5 mL blood. Nine of the patients' blood samples were processed with both... (More)
Cytokeratin 20 (CK20) is a well-established marker for colon epithelium. Herein, we suggest that CK20 is a biomarker for detecting circulating tumor cells (CTCs) in patients with metastatic colorectal cancer. Blood specimens (7.5 mL) were collected during surgery after liver mobilization from 25 patients with colorectal cancer. The FDA approved CellSearch™ system and two panels of antibodies against cytokeratins, cytokeratin 8, 18 and 19 (CK8/18/19) and CK8/18/19/20, were used for the detection of CTCs. All the patients' samples were processed using the anti-CK8/18/19 panel. The number of detected CTCs was low, 52% of the patients lacked CTCs and 40% had ≤ 2 CTCs/7.5 mL blood. Nine of the patients' blood samples were processed with both antibody panels. The detection rate of CTCs was significantly higher using the anti-CK8/18/19/20 panel compared with the anti-CK8/18/19 panel, p-value 0.0078. Our data show that inclusion of CK20 as a biomarker efficiently improves the detection of CTCs in colorectal cancer patients. The finding in our study is of clinical importance since a new prognostic biomarker would provide an important tool in individual clinical decision-making for colorectal cancer patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Letters
volume
358
issue
1
pages
43 - 46
publisher
Elsevier
external identifiers
  • pmid:25528628
  • wos:000349507300006
  • scopus:84921354751
ISSN
1872-7980
DOI
10.1016/j.canlet.2014.12.024
language
English
LU publication?
yes
id
c914de8a-7808-4ab4-a04a-f342a656776e (old id 4905847)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25528628?dopt=Abstract
date added to LUP
2015-01-07 15:28:42
date last changed
2017-07-02 03:05:16
@article{c914de8a-7808-4ab4-a04a-f342a656776e,
  abstract     = {Cytokeratin 20 (CK20) is a well-established marker for colon epithelium. Herein, we suggest that CK20 is a biomarker for detecting circulating tumor cells (CTCs) in patients with metastatic colorectal cancer. Blood specimens (7.5 mL) were collected during surgery after liver mobilization from 25 patients with colorectal cancer. The FDA approved CellSearch™ system and two panels of antibodies against cytokeratins, cytokeratin 8, 18 and 19 (CK8/18/19) and CK8/18/19/20, were used for the detection of CTCs. All the patients' samples were processed using the anti-CK8/18/19 panel. The number of detected CTCs was low, 52% of the patients lacked CTCs and 40% had ≤ 2 CTCs/7.5 mL blood. Nine of the patients' blood samples were processed with both antibody panels. The detection rate of CTCs was significantly higher using the anti-CK8/18/19/20 panel compared with the anti-CK8/18/19 panel, p-value 0.0078. Our data show that inclusion of CK20 as a biomarker efficiently improves the detection of CTCs in colorectal cancer patients. The finding in our study is of clinical importance since a new prognostic biomarker would provide an important tool in individual clinical decision-making for colorectal cancer patients.},
  author       = {Welinder, Charlotte and Jansson, Bo and Lindell, Gert and Wenner, Jörgen},
  issn         = {1872-7980},
  language     = {eng},
  number       = {1},
  pages        = {43--46},
  publisher    = {Elsevier},
  series       = {Cancer Letters},
  title        = {Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer.},
  url          = {http://dx.doi.org/10.1016/j.canlet.2014.12.024},
  volume       = {358},
  year         = {2015},
}